Thomas Hennessey
Director/Board Member bij AutoGenomics, Inc.
Profiel
Thomas V. Hennessey zit in de raad van bestuur van AutoGenomics, Inc. In het verleden was hij Chief Operating & Financial Officer van AutoImmune, Inc., Chief Operating & Financial Officer van Boston Scientific Corp., Chief Operating & Financial Officer van Cambridge Heart, Inc., Chief Financial Officer van LumeRx, Inc., Chief Operating & Financial Officer van Photovac, Inc., Chief Operating & Financial Officer van Behring Diagnostics Business, Chief Operating & Financial Officer van PHT Corp., Chief Operating & Financial Officer van Medical Diagnostics, Inc. en Chief Operating & Financial Officer van SonaMed Corp. Thomas V. Hennessey behaalde een doctorale graad en een undergraduate graad aan het Massachusetts Institute of Technology en een MBA aan de Harvard Business School.
Actieve functies van Thomas Hennessey
Bedrijven | Functie | Begin |
---|---|---|
AutoGenomics, Inc.
AutoGenomics, Inc. Medical SpecialtiesHealth Technology AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA. | Director/Board Member | 01-01-2008 |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | Director/Board Member | - |
Eerdere bekende functies van Thomas Hennessey
Bedrijven | Functie | Einde |
---|---|---|
Photovac, Inc.
Photovac, Inc. Medical SpecialtiesHealth Technology Part of Applied Biosystems, Inc., Photovac, Inc. is a Canadian company that specializes in portable environmental instruments. The private company is based in Markham, Canada. Photovac was acquired by Applera Corp. on April 13, 1995. | Director of Finance/CFO | 01-01-2003 |
PHT Corp.
PHT Corp. Packaged SoftwareTechnology Services PHT Corp. designs and develops software applications. The firm offers biopharmaceutical clients comprehensive services for acquiring, managing, and analyzing data collected directly from patients through all phases of clinical development. Its electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from smartphones, tablets, and the web. The company was founded by Stephen Raymond in 1994 and is headquartered in Boston, MA. | Director of Finance/CFO | - |
SonaMed Corp.
SonaMed Corp. Medical SpecialtiesHealth Technology SonaMed Corp. designs, develops, manufactures and markets automated, internet ready screening and monitoring systems for the hospital, physician's office and home monitoring markets. The company was founded by William Ford Dolphin in 1994 and is headquartered in Waltham, MA. | Director of Finance/CFO | - |
CAMBRIDGE HEART, INC. | Director of Finance/CFO | - |
BOSTON SCIENTIFIC CORPORATION | Director of Finance/CFO | - |
Opleiding van Thomas Hennessey
Massachusetts Institute of Technology | Graduate Degree |
Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BOSTON SCIENTIFIC CORPORATION | Distribution Services |
Bedrijven in privébezit | 10 |
---|---|
AutoImmune, Inc.
AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Health Technology |
Cambridge Heart, Inc.
Cambridge Heart, Inc. Medical SpecialtiesHealth Technology Cambridge Heart, Inc. engages in the development and commercialization of products for the non-invasive diagnosis of cardiac disease. The company was founded by Jeffrey M. Arnold and Jordan S. Davis on January 16, 1990 and is headquartered in Tewksbury, MA. | Health Technology |
LumeRx, Inc.
LumeRx, Inc. Medical SpecialtiesHealth Technology LumeRx, Inc. develops radiation technology that eliminates bacteria. It provides minimally invasive and light-based devices for the treatment of peptic ulcer disease. The company was founded by Robert A. Ganz and is headquartered in Newton, MA. | Health Technology |
AutoGenomics, Inc.
AutoGenomics, Inc. Medical SpecialtiesHealth Technology AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA. | Health Technology |
Medical Diagnostics, Inc. | Health Services |
PHT Corp.
PHT Corp. Packaged SoftwareTechnology Services PHT Corp. designs and develops software applications. The firm offers biopharmaceutical clients comprehensive services for acquiring, managing, and analyzing data collected directly from patients through all phases of clinical development. Its electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from smartphones, tablets, and the web. The company was founded by Stephen Raymond in 1994 and is headquartered in Boston, MA. | Technology Services |
Behring Diagnostics Business
Behring Diagnostics Business Medical SpecialtiesHealth Technology Part of Siemens AG, Behring Diagnostics Business provides diagnostic services. | Health Technology |
Photovac, Inc.
Photovac, Inc. Medical SpecialtiesHealth Technology Part of Applied Biosystems, Inc., Photovac, Inc. is a Canadian company that specializes in portable environmental instruments. The private company is based in Markham, Canada. Photovac was acquired by Applera Corp. on April 13, 1995. | Health Technology |
SonaMed Corp.
SonaMed Corp. Medical SpecialtiesHealth Technology SonaMed Corp. designs, develops, manufactures and markets automated, internet ready screening and monitoring systems for the hospital, physician's office and home monitoring markets. The company was founded by William Ford Dolphin in 1994 and is headquartered in Waltham, MA. | Health Technology |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | Health Technology |